Chinese Heparin API Manufacturer Not Inspected By SFDA
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's State FDA has never inspected an API manufacturer that may be linked to a safety scare over Baxter Healthcare's injectable heparin, officials confirmed to PharmAsia News
You may also be interested in...
China To Step Up Supervision Of APIs And Drug Excipients – PDA-FDA Supply Chain Conference
SHANGHAI - China's State FDA is planning to launch a drug master file system to establish better controls for active pharmaceutical ingredients and drug excipients
China To Step Up Supervision Of APIs And Drug Excipients – PDA-FDA Supply Chain Conference
SHANGHAI - China's State FDA is planning to launch a drug master file system to establish better controls for active pharmaceutical ingredients and drug excipients
China To Step Up Supervision Of APIs And Drug Excipients – PDA-FDA Supply Chain Conference
China’s State FDA plans to launch a drug master file system and may integrate that system into existing regulations.